3 New Strong Buy Ratings from Top-Rated Analysts: 06/26/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Pacs Group (PACS) — Healthcare services play earns unanimous Wall Street backing.
- Ani Pharmaceuticals (ANIP) — Rare disease leader eyes 50% upside ahead.
- Beone Medicines (ONC) — Top mid-cap oncology pick targets 60% upside.
P.S. Want a bonus pick every week? Join our weekly Live training at 7pm every Monday to access our Editor-in-Chief’s Trade of the Week. Sign up for the next one here (completely complimentary!)
A note from our sponsors...
The ONLY AI opportunity you should be looking at
This is the ONLY AI wealth-building opportunity you should be watching right now.
No. It's not about Nvidia, Tesla, or Meta...
It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.
This new opportunity will change the market and make investors a lot of money.
That's why it has received a $500 billion commitment from President Trump himself...
Learn more about this little-known company here >>>
1. Pacs Group (NYSE: PACS)
Unanimous bullish consensus from Wall Street is a rare thing — and PACS Group has it. The company provides services in the medical care industry, operating as a relatively new public company since April 2024 but already establishing strong market positioning, capitalizing on structural trends in healthcare services delivery.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $38.90 — get current quote
Max 1-year forecast: $52.00
Why we're watching:
- Analyst support: PACS enjoys perfect bullish consensus from Wall Street with 4 analysts covering the stock. See the recommendations
- Truist Securities' David S Macdonald (a top 8% rated analyst) recently raised his price target to $52 (over 30% implied upside!) following Q1 2026 earnings, attributing the increase to the quarter's strong results and management's updated FY 2026 guidance.
- In his analyst commentary, MacDonald noted management's optimism about future earnings following a quarter where the company reported Q1 EPS of $1.56 with full-year guidance of $2.26, suggesting robust earnings acceleration ahead.
- Industry ranking context: Pacs Group is currently the 4th highest-rated stock in the Medical Care Facility industry, which has an Industry Rating of A, positioning the company in a high-quality sector with strong fundamentals.
- Zen Rating highlights: PACS earns an overall A from our Zen Ratings, which amounts to a Strong Buy recommendation. This grade doesn’t come lightly — it means that PACS passed our 115-factor fundamental review with flying colors.
- Component Grades: The company demonstrates solid fundamental strength with Momentum earning a B grade, Safety also at B, and Sentiment leading with an A grade, while Financials receive a C reflecting the company's earlier stage of public market operations. See all 7 Component Grades here
2. Ani Pharmaceuticals (NASDAQ: ANIP)
Cortrophin Gel is fueling a quiet transformation at ANI Pharmaceuticals. The biopharmaceutical company concentrates on the development, production, and commercialization of both proprietary branded and generic pharmaceutical products — and the company is now driving growth through its rare disease franchise, with Cortrophin Gel leading the charge in 2026.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $82.72 — get current quote
Max 1-year forecast: $124.00
Why we're watching:
- Analyst support: While coverage is very slim with just 1 recommendation at present, it’s bullish: ANIP receives a Strong Buy recommendation with a compelling $124 price target representing 50% upside potential from current levels. See forecast updates here
- That’s from Guggenheim researcher Vamil Divan (a top 4% rated analyst), who maintains his Strong Buy rating with a $124 price target, reflecting confidence in the company's rare disease strategy and Cortrophin Gel's commercial trajectory.
- The stock trades at an attractive valuation of just 9.8x forward earnings despite strong growth prospects, with analysts projecting EPS growth of 134% in the coming year driven by the rare disease portfolio expansion.
- Industry ranking context: ANI Pharmaceuticals is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B, demonstrating strong relative positioning in a quality sector.
- Zen Rating highlights: ANIP earns an overall Strong Buy recommendation from the Zen Ratings, with a grade of A. Only the top 5% of stocks tracked are in this tier!
- Component Grades: The company shows balanced strength with Value earning an A grade, Sentiment and Financials both receiving B grades, reflecting positive analyst and market perception of the company's strategic direction. See all 7 Component Grades here
3. Beone Medicines (NASDAQ: ONC)
A global oncology powerhouse is quietly building one of biotech's most impressive pipelines. BeOne Medicines (formerly BeiGene) stands as a prominent global oncology enterprise committed to identifying, advancing, and commercializing cutting-edge cancer therapies — with its foundational hematology franchise anchored by BRUKINSA, the best-in-class BTK inhibitor driving sustained growth, while an impressive solid tumor pipeline creates multiple catalysts ahead.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $277.12— get current quote
Max 1-year forecast: $436.00
Why we're watching:
- Analyst support: ONC enjoys broad Wall Street backing with a Strong Buy consensus among the 7 analysts covering the stock. See the recommendations here
- Guggenheim's Michael Schmidt (a top 2% rated analyst) recently raised his price target to $420 (over 50% upside) following Q1 earnings, calling ONC Guggenheim's "Top Mid-Cap Pick" and citing the quarter's revenue beat and FY 2026 guidance raise.
- In detailed analyst commentary, Schmidt highlighted that "BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data" with Q1 revenue of $1.51B and updated full-year guidance of $6.3B to $6.5B.
- Industry ranking context: BeOne Medicines is currently the 13th highest-rated stock out of over 400 in the Biotech industry.
- Zen Rating highlights: ONC passed our 115-factor fundamental review with great scores — earning it a spot in the top tier of stocks we track, an A rating or Strong Buy recommendation.
- Component Grades: The stock shows solid balanced strength across metrics with Growth and Financials both earning B grades, Value at B, and AI capabilities also rated B, reflecting the company's innovative pipeline and commercial execution. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.